ESC Heart Failure

Article	Citations
Pre‐operative risk factors for driveline infection in left ventricular‐assist device patients	104
Serum autotaxin as a novel prognostic marker in patients with non‐ischaemic dilated cardiomyopathy	94
Echocardiographic pressure–strain loop‐derived stroke work of the right ventricle: validation against the gold standard	58
Uncovering the genetic links of SARS‐CoV‐2 infections on heart failure co‐morbidity by a systems biology approach	55
Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIAST‐CHF study	54
Feasibility of physiological pacing rate in cardiac resynchronization therapy	53
2024 update in heart failure	52
Correlation between coronary calcification and cardiac structure in non‐dialysis patients with chronic kidney disease	51
Myocardial viability assessment during Impella support with 18‐fluorodesoxyglucose PET imaging	47
Left atrial reverse remodelling predicts prognosis in patients with acute decompensated heart failure	40
The chronic heart failure evolutions: Different fates and routes	39
Letter to editor regarding the article ‘Prediction of heart failure events based on physiologic sensor data’	39
Explainable machine learning and online calculators to predict heart failure mortality in intensive care units	37
Device‐therapy in chronic heart failure: Cardiac contractility modulation versus cardiac resynchronization therapy	37
Prevalence and characteristics of upfront diuretic resistance in acute heart failure: The P‐Value‐AHF study	36
Awareness, access, and adoption of natriuretic peptides for diagnosis of heart failure	36
Assessing congestion using estimated plasma volume status: Ready for prime time?	36
Acyl ghrelin increases cardiac output while preserving right ventricular‐pulmonary arterial coupling in heart failure	36
Reply to letter to the editor: ‘Evaluating imaging modalities for pulmonary congestion: Beyond chest X‐ray and LDCT’	34
Outcomes of cardiac resynchronization therapy (CRT) in cardiac sarcoidosis patients with a range of ejection fractions	34
Meta‐analysis of cardiac magnetic resonance in prognosticating left ventricular function in peripartum cardiomyopathy	34
Heart failure associated with imported malaria: a nationwide Danish cohort study	33
Prognostic value of hypoxaemic burden from overnight oximetry in heart failure with preserved ejection fraction	33
Longest survivor of pulmonary atresia with ventricular septal defect without surgical intervention	33
Expression of soluble ST2 in patients with essential hypertension and its relationship with left ventricular hypertrophy	33

Machine learning‐based model for predicting 1 year mortality of hospitalized patients with heart failure	33
Incidence and predictors of heart failure with improved ejection fraction category in a HFrEF patient population	33
Clinical course of patients with hypertrophic cardiomyopathy away from tertiary referral care	32
Transcatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a systematic review and meta‐analysis	30
Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline‐induced takotsubo‐like syndrome	30
Genetic variation in sodium glucose co‐transporter 1 and cardiac structure and function at middle age	30
Lumican accumulates with fibrillar collagen in fibrosis in hypertrophic cardiomyopathy	29
Left atrial structural and mechanical remodelling in heart failure with reduced ejection fraction	29
Impact of age on characteristics, performance measures and outcomes of inpatients for heart failure in Beijing, China	29
Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients	29
Global longitudinal strain and outcome after endoscopic mitral valve repair	29
	29
Diverging role of epicardial adipose tissue across the entire heart failure spectrum	29
Different activation of MAPKs and Akt/GSK3β after preload vs. afterload elevation	29
Smoking and heart failure: a Mendelian randomization and mediation analysis	29
Hospitalization for acute heart failure during non‐working hours impacts on long‐term mortality: the REPORT‐HF registry	29
Importance of the ‘area under the curve’ from serial NT‐proBNP measurements during treatment with sacubitril/valsartan	29
Hypotension on cardiopulmonary stress test predicts 90 day mortality after LVAD implantation in INTERMACS 3–6 patients	28
Revascularization for controlling hypertension and improving cardiorenal failure in Leriche syndrome	28
Inhalation of publicly available indoor insecticide spray caused myocardial infarction type II: a case report	27
Disparities in clinical features and outcomes of peripartum cardiomyopathy in high versus low prevalent regions in Nigeria	27
Oral milrinone for management of refractory right ventricular failure in patients with left ventricular assist devices	27
Issue Information	27
Urinary drug metabolite testing in chronic heart failure patients indicates high levels of adherence with life‐prolonging therapies	27
Association of chronic heart failure with mortality in old intensive care patients suffering from Covid‐19	27
Minimal subphenotyping model for acute heart failure with preserved ejection fraction	26
Synchronized diaphragmatic stimulation: a case report of a novel extra‐cardiac intervention for chronic heart failure	26
Regional management of worsening heart failure: rationale and design of the CHAIN‐HF registry	26
With appreciation	25
The development and initial validation of the PROMIS®+HF‐27 and PROMIS+HF‐10 profiles	25
Oral iron supplementation in patients with heart failure: a systematic review and meta‐analysis	25
Prevalence and prognostic impact of left ventricular systolic dysfunction or pulmonary congestion after acute myocardial infarction	25
Resistin and risks of incident heart failure subtypes and cardiac fibrosis: the Multi‐Ethnic Study of Atherosclerosis	25
Systolic dysfunction and mortality in critically ill patients: more data are needed to believe in this association!	25
Asymptomatic COVID‐19 and ST‐elevation myocardial infarction in young adults: lessons learned from two similar cases	25
Acute and chronic exercise training in patients with Class II pulmonary hypertension: effects on haemodynamics and symptoms	25
Identification of vital modules and genes associated with heart failure based on weighted gene coexpression network analysis	25
Familial risk of dilated and hypertrophic cardiomyopathy: a national family study in Sweden	25
Role of selenium in the pathophysiology of cardiorenal anaemia syndrome	25
Atrial appendage closure in patients with heart failure and atrial fibrillation: industry‐independent single‐centre study	24
Creating an impact, not an impression: ESC Heart Failure in its seventh year	24
Global differences in acute heart failure treatment: analysis of the STRONG‐HF site feasibility questionnaire	24
CA‐125 variation in acute heart failure: a single‐centre analysis	24
Vagus nerve stimulation‐induced stromal cell‐derived factor‐l alpha participates in angiogenesis and repair of infarcted hearts	24
Prediction of cardiac events with non‐contrast magnetic resonance feature tracking in patients with ischaemic cardiomyopathy	24
Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry	24
Circ_0001206 regulates miR‐665/CRKL axis to alleviate hypoxia/reoxygenation‐induced cardiomyocyte injury in myocardial infarction	24
	24
Impaired renal function and mortalities in acute heart failure with different phenotypes	24
Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry	24

	23
Acylation‐stimulating protein and heart failure progression in arrhythmogenic right ventricular cardiomyopathy	23
Exercise training and high‐sensitivity cardiac troponin T in patients with heart failure with reduced ejection fraction	23
The predictive value of self‐compassion for psychological adjustment in left ventricular assist device patients: an observational study	23
A case series of cardiac amyloidosis patients supported by continuous‐flow left ventricular assist device	23
A comparison between hospital follow‐up and collaborative follow‐up in patients with acute heart failure	23
Missed opportunities in the diagnosis of heart failure: a real‐world assessment	22
Incidence and impact of atrial fibrillation in heart failure patients: real‐world data in a large community	22
Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment	22
Iron therapy and severe arrhythmias in HFrEF: rationale, study design, and baseline results of the RESAFE‐HF trial	22
Characterization of heart failure patients with reverse left ventricular remodelling post‐angiotensin receptor blockers/neprilysin inhibitors therapy	22
Early left ventricular unloading after extracorporeal membrane oxygenation: rationale and design of EARLY‐UNLOAD trial	22
Issue Information	22
Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan	22
	22
Detection of transthyretin amyloid cardiomyopathy by automated data extraction from electronic health records	22
Atrial fibrillation ablation in patients with arrhythmia‐induced cardiomyopathy: a prospective multicentre study	22
Aberrant static and dynamic functional network connectivity in heart failure with preserved ejection fraction	22
Intestinal permeability evaluation in patients with chronic Chagas heart failure	22
Long‐term administration of intravenous inotropes in advanced heart failure	22
Incident heart failure and myocardial infarction in sodium‐glucose cotransporter‐2 vs. dipeptidyl peptidase‐4 inhibitor users	21
Underdiagnosed Roifman syndrome manifested as non‐ischaemic cardiomyopathy: a case report	21
	21
Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real‐world study	21
The restricted mean survival time as a replacement for the hazard ratio and the number needed to treat in long‐term studies	21
Sex differences in congestive markers in patients hospitalized for acute heart failure	21
Predictive value of global longitudinal strain by left ventricular ejection fraction	21
Acute heart failure and iron deficiency: a prospective, multicentre, observational study	21
Cardiac computed tomography‐derived myocardial tissue characterization after anthracycline treatment	20
Clinically suspected lethal viral myocarditis combined with encephalitis: a COVID‐19 vaccine complication	20
Assessment of the impact of different N terminal pro brain natriuretic peptide thresholds on echocardiography services	20
Admission NT‐proBNP and outcomes in patients without history of heart failure hospitalized with COVID‐19	20
Sudden cardiac death after acute decompensation in heart failure patients: implications of discharge haemoglobin levels	20
Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients	20
Impact of adherence to guideline‐directed therapy on risk of death in HF patients across an ejection fraction spectrum	20
	20
Effectiveness of motivational interviewing on health‐service use and mortality: a secondary outcome analysis of the MOTIVATE‐HF trial	20
Myocardial ultrastructure can augment genetic testing for sporadic dilated cardiomyopathy with initial heart failure	20
Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis	20
Cushing's syndrome presenting as non‐atherosclerotic myocardial infarction and heart failure	20
Left atrial unloading with an 8 mm septal cutting balloon to treat postcapillary pulmonary hypertension: a case report	20
Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study	19
The influence of inhibiting renal neural regeneration on the efficacy of renal denervation to chronic heart failure	19
Right ventricular expression of NT‐proBNP adds predictive value to REVEAL score in patients with pulmonary arterial hypertension	19
Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry	19
Rationale and design of the AMULET study: A new Model of telemedical care in patients with heart failure	19
Heart transplantation in patients bridged with mechanical circulatory support: outcome comparison with matched controls	19
Effect of a strategy of comprehensive vasodilation versus usual care on health‐related quality of life among patients with acute heart failure	19
Advanced isolated light chain amyloid cardiomyopathy with negative immunofixation and normal free light chain ratio	19
Iron deficiency in heart failure patients: the French CARENFER prospective study	19
Interleukin‐1 blockade in heart failure: an on‐treatment and off‐treatment cardiorespiratory fitness analysis	19
Association of perivascular fat attenuation on computed tomography and heart failure with preserved ejection fraction	19
Integrated care for older multimorbid heart failure patients: protocol for the ESCAPE randomized trial and cohort study	19
Multimodality assessment of heart failure with preserved ejection fraction skeletal muscle reveals differences in the machinery of energy fuel metabolism	19
New insight: particle flow rate from the airways as an indicator of cardiac failure in the intensive care unit	18
MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation	18
Hypertrophic cardiomyopathy with heart failure and ST‐segment elevation of the lateral wall	18
Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT‐HF risk model	18
Outflow graft obstruction after left ventricular assist device implantation: a retrospective, single‐centre case series	18
Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance	18
Bail‐out treatment of pulmonary embolism using a large‐bore aspiration mechanical thrombectomy device	18
Association of adherence to a 3 month cardiac rehabilitation with long‐term clinical outcomes in heart failure patients	18
Prognostic role of high‐sensitivity cardiac troponin T in patients with cardiac sarcoidosis: insights from ILLUMINATE‐CS	18
Increased acylcarnitines in infant heart failure indicate fatty acid oxidation inhibition: towards therapeutic options?	18
GDF‐15 at admission predicts cardiovascular death, heart failure, and bleeding outcomes in patients with CAD	18
Effects of intravenous furosemide plus small‐volume hypertonic saline solutions on markers of heart failure	18
Impact of bridging with left ventricular assist device on right ventricular function following heart transplantation	18
Heart failure and trimethylamine N‐oxide: time to transform a ‘gut feeling’ in a fact?	18
Cardiovascular health metrics and risk of heart failure in a Finnish population: a prospective cohort study	18
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues	18
Heart failure with preserved ejection fraction in haemodialysis patients: prevalence, diagnosis, risk factors, prognosis	18
Age‐related survival after alcohol septal ablation in hypertrophic obstructive cardiomyopathy	18
The protective effect of LCZ696 in coxsackievirus B3‐induced acute viral myocarditis mice	18
Association of anaemia and all‐cause mortality in patients with ischaemic heart failure varies by renal function status	18
Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure	18
Real‐world outcomes in cardiac resynchronization therapy patients: Primary results of the SMART registry	17
The prognostic value of heart rate at discharge in acute decompensation of heart failure with reduced ejection fraction	17
Plasma amino acid profiling improves predictive accuracy of adverse events in patients with heart failure	17
Neutrophils pro‐inflammatory and anti‐inflammatory cytokine release in patients with heart failure and reduced ejection fraction	17
Reaching consensus for unified medical language in Fontan care	17

Exercise‐induced B‐lines in heart failure with preserved ejection fraction occur along with diastolic function worsening	17
The use of MitraClip for nonobstructive hypertrophic cardiomyopathy with mixed severe mitral valve regurgitation	17
Public assistance in patients with acute heart failure: a report from the KCHF registry	17
N‐terminal pro brain natriuretic peptide reference values in community‐dwelling older adults	17
Right atrial pressure represents cumulative cardiac burden in heart failure with preserved ejection fraction	17
Real‐world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction	17
Cardiac involvement in patients recovering from Delta Variant of COVID‐19: a prospective multi‐parametric MRI study	16
Cardiac allograft vasculopathy and donor age affecting permanent pacemaker implantation after heart transplantation	16
Lung diffusion capacity correlates with pre‐implant pulmonary hypertension and predicts outcome after LVAD implantation	16
Comparison of feasibility and results of frailty assessment methods prior to left ventricular assist device implantation	16
Daprodustat for anaemia in patients with heart failure and chronic kidney disease: A randomized controlled study	16
Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines	16
Serum angiotensin‐converting enzyme levels indicating early sarcoidosis diagnosis and immunosuppressive therapy efficacy	16
Use of serial changes in biomarkers vs. baseline levels to predict left ventricular remodelling after STEMI	16
Influence of serum transferrin concentration on diagnostic criteria for iron deficiency in chronic heart failure	16
Dynamic risk stratification using Markov chain modelling in patients with chronic heart failure	16
Characteristics and management of very elderly patients with heart failure: a retrospective, population cohort study	16
Cabergoline treatment promotes myocardial recovery in peripartum cardiomyopathy	16
Factors influencing left ventricular thrombus resolution and its significance on clinical outcomes	16
Optimizing exercise testing‐based risk stratification to predict poor prognosis after acute heart failure	16
The effect of immunosuppressive therapy on cardiac involvements in anti‐mitochondrial antibody‐positive myositis	15
Prognostic significance of serum chloride level in heart failure patients with preserved ejection fraction	15
Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction	15
Serum microRNAs are key predictors of long‐term heart failure and cardiovascular death after myocardial infarction	15
Shear wave elastography to evaluate hepatic damage in heart failure	15
Prognostic significance of the HFA‐PEFF score in patients with heart failure with preserved ejection fraction	15
Myocardial strain for heart failure with preserved ejection fraction but without diastolic dysfunction	15
Prevalence and impact of malnutrition on readmission among hospitalized patients with heart failure in China	15
Machine learning approach to stratify complex heterogeneity of chronic heart failure: A report from the CHART‐2 study	15
Cardiac rehabilitation with intermittent myocardial ischaemia as a new therapeutic option in refractory angina?	15
Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis	15
Conduction system pacing and atrioventricular node ablation in heart failure: The PACE‐FIB study design	15
Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF	15
High platelet reactivity is a predictor of left ventricular remodelling in patients with acute myocardial infarction	15
Multiparameter diagnostic sensor measurements in heart failure patients presenting with SARS‐CoV‐2 infection	15
Discordance between estimated and measured changes in plasma volume among patients with acute heart failure	15
Therapeutic approach in heart failure with poor diuretic response: peripheral ultrafiltration vs. conventional treatment	15
Circulating microRNAs and cardiomyocyte proliferation in heart failure patients related to 10 years survival	15
Evaluation of phosphodiesterase 9A as a novel biomarker in heart failure with preserved ejection fraction	14
The Critical Role of Comorbidities in Managing Heart Failure with Preserved Ejection Fraction (HFpEF)	14
Prognostic value of the NEWS + Lactate score in patients with decompensated heart failure in the emergency department	14
Feasibility of patient‐performed lung ultrasound self‐exams (Patient‐PLUS) as a potential approach to telemedicine in heart failure	14
Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial	14
Health‐related quality of life among transthyretin amyloid cardiomyopathy patients	14
Activating transcription factor 4 drives the progression of diabetic cardiac fibrosis	14
Dynamic aspects of ventricular interaction during exercise in HFpEF and in pre‐capillary pulmonary hypertension	14
Left ventricular diastolic dysfunction worsens prognosis in patients with heart failure due to dilated cardiomyopathy	14
Functional classification of left ventricular remodelling: prognostic relevance in myocardial infarction	14
Burden of hospitalizations in newly diagnosed heart failure patients in Poland: real world population based study in years 2013–2019	14
HOXA cluster antisense RNA 2 elevates KIAA1522 expression through microRNA‐520d‐3p and insulin like growth factor 2 mRNA binding protein 3 to promote the growth of vascular smooth muscle cells in thor	14
The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle	14
Sacubitril/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial	14
The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis	14
Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis	14
Judgement of the multidisciplinary team is an important predictor of mortality after cardiac resynchronization therapy	14
Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction	14
Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials	14
Impact of global warming on weight in patients with heart failure during the 2019 heatwave in France	14
Clinical characteristics and frailty status in heart failure with preserved vs. reduced ejection fraction	13
Use of liver stiffness measurements in acute decompensated heart failure: new applications of a non‐invasive technique	13
Impact of heart failure on all‐cause mortality in COVID‐19: findings from the Eurasian International Registry	13
Sex differences in natural history of cardiovascular magnetic resonance‐ and biopsy‐proven lymphocytic myocarditis	13
Fibrosis‐4 index reflects right ventricular function and prognosis in heart failure with preserved ejection fraction	13
Heart failure and atrial fibrillation: tachycardia‐mediated acute decompensation	13
Urinary N‐terminal pro‐brain natriuretic peptide: prognostic value in patients with acute chest pain	13
Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems	13
Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries	13
Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure	13
Insulin‐like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence	13
Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction	13
Self‐care perception and behaviour in patients with heart failure: A qualitative and quantitative study	13
Association of congestion with worsening renal function in acute decompensated heart failure according to age	13
Heart failure related to adult congenital heart disease: prevalence, outcome and risk factors	13
Primary results from the Japanese Heart Failure and Sudden Cardiac Death Prevention Trial (HINODE)	13
Systemic immune‐inflammation index as a prognostic marker for advanced chronic heart failure with renal dysfunction	13
Models of cardiovascular surgery biobanking to facilitate translational research and precision medicine	13
Cardiovascular and metabolic determinants of quality of life in patients with cancer	13
Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)	13
In‐hospital changes in the red blood cell distribution width and mortality in critically ill patients with heart failure	13
Rnf144b alleviates the inflammatory responses and cardiac dysfunction in sepsis	13
Comparison of liver fibrosis scores for predicting mortality and morbidity in heart failure with preserved ejection fraction	13
Real‐time pulmonary artery pressure monitoring in heart failure patients: an updated cost‐effectiveness analysis	13
Non‐invasive home telemonitoring in patients with decompensated heart failure: a systematic review and meta‐analysis	13
Usefulness of ventilatory inefficiency in predicting prognosis across the heart failure spectrum	13
Prognostic value of lung ultrasound in patients hospitalized for heart disease irrespective of symptoms and ejection fraction	13
Remote management of worsening heart failure to avoid hospitalization in a real‐world setting	13
Reductions in renin‐angiotensin system inhibitors following hospitalization for heart failure	12
Clinical profile, associated events and safety of vericiguat in a real‐world cohort: The VERITA study	12
IL‐6 and hsCRP predict cardiovascular mortality in patients with heart failure with preserved ejection fraction	12
Cardiac biomarkers for screening and prognostication of cardiac dysfunction in critically ill patients	12
Telehealth‐aided outpatient management of acute heart failure in a specialist virtual ward compared with standard care	12
Emergent role of dynamic optimization in cardiac resynchronization therapy: Systematic review and network meta‐analysis	12
Time to intravenous diuretic administration in patients hospitalized with heart failure: An observational study	12
The D‐HCM score, a new diagnostic tool for distinguishing hypertrophic cardiomyopathy from hypertensive cardiopathy	12
Corrigendum	12